Medtronic Shares Dip 0.45% on Surging $0.97 Billion Volume, Ranking 132th in Market Activity

On October 1, 2025, Medtronic (MDT) closed with a 0.45% decline, despite a surge in trading activity. The stock saw a volume of $0.97 billion, reflecting a 44.66% increase compared to the previous day, ranking it 132th in market activity. The movement came amid mixed signals from its recent product pipeline updates and regulatory developments.

Recent reports highlighted Medtronic’s progress in its cardiovascular device trials, with preliminary data from a key study showing improved patient outcomes. However, analysts noted that the results, while positive, fell short of expectations for long-term efficacy metrics. This tempered investor enthusiasm, particularly as the company faces ongoing competition in the implantable device segment.

Regulatory updates also played a role. The FDA extended its review timeline for a next-generation spinal stimulation system, citing the need for additional safety data. While the delay is not uncommon for complex medical devices, it raised questions about potential delays in market entry. Market participants remain cautious ahead of the final agency decision, which is expected in early 2026.

To run this back-test accurately, I need to pin down a few practical details: Market universe—Should we look at U.S.-listed common stocks only (NYSE + NASDAQ), or a different market? Trade timing & prices—Enter at each day’s close and exit at the next day’s close (default), or would you prefer open-to-open, close-to-open, etc.? Weighting & cash allocation—Equal-weight the 500 names each day (default), or weight by volume, market-cap, etc.? Transaction costs / slippage—Assume zero cost (default), or apply a specific commission + slippage rate? If the defaults above work for you, let me know and I’ll proceed with the back-test from 2022-01-03 (first trading day of 2022) through today.